Molecular Partners vs Relay Therapeutics
MOLN and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MOLN and RLAY compare
Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −100% for Molecular Partners).
Relay Therapeutics scores higher on the StockData Score (10 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MOLN | RLAY |
|---|---|---|
| Size and price | ||
| Market cap | – | $4.3B |
| Share price | $3.09 | $19.72 |
| Change, 1 year | −27.3% | 220% |
| Change, 5 years | −70.4% | −42.8% |
| Beta (5Y) | 0.90 | 1.96 |
| Employees | 34 | 192 |
| StockData Score | ||
| Total score | 1 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 418× |
| P/B | – | 5.3× |
| Growth | ||
| Revenue growth (TTM) | −100% | 23.9% (better) |
| Revenue growth, 5Y average | – | −28.6% |
| Profitability | ||
| Operating margin | – | −3095% |
| Net margin | – | −2837% |
| Return on equity | – | −41.2% |
| Return on invested capital | – | −41.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −11.5× | – |
| Current ratio | 7.27 | 14.62 (better) |
| Altman Z-score | – | 27.77 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 8.9% | 113% |
| Held by insiders | 0.00% | 24.5% |
| Insider net buying, 12 months | – | −$129M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 26.4% |
Go deeper
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.